此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

Investigating Patient Satisfaction With Oral Anti-Cancer Treatment (IPSOC)

2014年9月19日 更新者:Sandra De Coster、KU Leuven

Investigating Patient Satisfaction With Oral Anti-Cancer Treatment. Prospective Non-interventional Non-controlled Multicenter Observational Study to Evaluate Aspects of Pharmaceutical Care in Patients With Advanced Renal Cell Carcinoma Treated With an Oral Anti-cancer Drug.

Prospective non-interventional non-controlled multicenter observational study to evaluate aspects of pharmaceutical care in patients with advanced renal cell carcinoma treated with an oral anti-cancer drug.

The main objective of this study is to evaluate the patient perspective in the treatment of advanced renal cell carcinoma with an oral anti-cancer drug.

The following aspects will be investigated:

  • Intrinsic desire for information about treatment.
  • Patient satisfaction with treatment information.
  • Patient satisfaction with treatment.
  • Medication adherence.
  • Health-related quality of life.
  • The role of different health care professionals in the treatment of RCC with oral drugs

This study should reveal information necessary for the development of pharmacotherapeutic care concepts that meet the needs of cancer patients treated with an oral anti-cancer drug over a long period.

研究概览

地位

完全的

研究类型

观察性的

注册 (实际的)

90

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习地点

      • Leuven、比利时、3000
        • Katholieke Universiteit Leuven - Klinische Farmacologie en Farmacotherapie

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

18年 及以上 (成人、年长者)

接受健康志愿者

不

有资格学习的性别

全部

取样方法

非概率样本

研究人群

mRCC patients starting with an oral anti-cancer treatment

描述

Inclusion Criteria:

  • Patients who are 18 years or older, and who can be contacted by phone and/or e-mail are eligible for the study

Exclusion Criteria:

  • Patients who are not able to understand Dutch or French will be excluded from the study

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

队列和干预

团体/队列
mRCC patients
Patients with metastatic renal cell carcinoma

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Medication adherence
大体时间:one year
At the first visit patients will receive their anti-cancer medication by the hospital in a pill box which electronically records openings cf. Medication Event Monitoring System (MEMS®, Aardex). The recorded information in this chip will be read in the hospital pharmacy each time the patient gets new capsules. This information is strictly confidential and can only be consulted by the research team at the KULeuven.
one year

次要结果测量

结果测量
措施说明
大体时间
Extent of Information Desire (EID)
大体时间:one year
Extent of information desire will be assessed, using a standardised questionnaire, at the start of the treatment, after approximately 1, 3 and 6 months of treatment and after about 12 months, at discontinuation of therapy or at end of study (whatever is earlier).
one year
Patient Satisfaction with Cancer Treatment Education (Ps-CaTE)
大体时间:one year
Satisfaction with cancer treatment information will be assessed, using a standardised questionnaire, after approximately 1, 3 and 6 months of treatment and after about 12 months, at discontinuation of therapy or at end of study (whatever is earlier).
one year
Morisky Medication Adherence Scale (MMAS)
大体时间:one year
Medication adherence will be assessed, using a standardised questionnaire, after approximately 1, 3 and 6 months of treatment and after about 12 months, at discontinuation of therapy or at end of study (whatever is earlier).
one year
Cancer Therapy Satisfaction Questionnaire (CTSQ)
大体时间:one year
Satisfaction with cancer treatment will be assessed, using a standardised questionnaire, after approximately 1, 3 and 6 months of treatment and after about 12 months, at discontinuation of therapy or at end of study (whatever is earlier).
one year
Functional Assessment of Cancer Therapy - General (FACT-G)
大体时间:one year
Health-related quality of life will be assessed, using a standardised questionnaire, at the start of the treatment, after approximately 1, 3 and 6 months of treatment and after about 12 months, at discontinuation of therapy or at end of study (whatever is earlier).
one year
Functional Kidney Symptom Index (FKSI)
大体时间:one year
Health-related quality of life will be assessed, using a standardised questionnaire, after approximately 1, 3 and 6 months of treatment and after about 12 months, at discontinuation of therapy or at end of study (whatever is earlier).
one year
Satisfaction With Pharmacist (SwiP)
大体时间:one year
Satisfaction with the pharmacist will be assessed, using a standardised questionnaire, after approximately 1, 3 and 6 months of treatment and after about 12 months, at discontinuation of therapy or at end of study (whatever is earlier).
one year

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

赞助

调查人员

  • 研究主任:Veerle Foulon, Professor、Katholieke Universiteit Leuven - Klinische Farmacologie en Farmacotherapie

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始

2011年2月1日

初级完成 (实际的)

2013年7月1日

研究完成 (实际的)

2013年7月1日

研究注册日期

首次提交

2014年7月3日

首先提交符合 QC 标准的

2014年9月19日

首次发布 (估计)

2014年9月25日

研究记录更新

最后更新发布 (估计)

2014年9月25日

上次提交的符合 QC 标准的更新

2014年9月19日

最后验证

2014年9月1日

更多信息

与本研究相关的术语

其他研究编号

  • VF/2010/03
  • s52586 (注册表标识符:Clinical Trial Center UZ Leuven)

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅